Swiss National Bank
CBIO

Swiss National Bank’s Crescent Biopharma CBIO Stock Holding History

Swiss National Bank’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-642
Closed -$277K – 2519
2019
Q3 		$277K Hold
642
– – ﹤0.01% 2465
2019
Q2 		$765K Buy
642
+13
+2% +$15.5K ﹤0.01% 2264
2019
Q1 		$784K Buy
629
+20
+3% +$22.9K ﹤0.01% 2194
2018
Q4 		$577K Buy
609
+17
+3% +$20.5K ﹤0.01% 2298
2018
Q3 		$852K Hold
592
– – ﹤0.01% 2233
2018
Q2 		$955K Buy
+592
New +$1.02M ﹤0.01% 2186

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Swiss National Bank's CBIO Position: Q4 2019 in Review

Swiss National Bank sold out of Crescent Biopharma (CBIO) in Q4 2019, closing a stake of 642 shares — an estimated $277K sold.

Swiss National Bank first reported a position in CBIO in Q2 2018 and held it in 6 quarters. The position peaked at $955K in Q2 2018. 78 funds tracked by Wall St. Rank hold CBIO as of Q4 2019.

  • Swiss National Bank reported no remaining Crescent Biopharma position as of Q4 2019 after selling out during the quarter.
  • Swiss National Bank sold 642 Crescent Biopharma shares in Q4 2019, an estimated $277K.
  • Swiss National Bank first reported a position in Crescent Biopharma in Q2 2018 and held it in 6 quarters.
  • Swiss National Bank's Crescent Biopharma position peaked at $955K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2019.

Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.